Ebola virus has a solution, Merck completes the vaccine clinical trial

Ebola virus used to be a small-scale outbreak in the past. It was only a horrible and mysterious subject in film and television literature. However, since the end of 2013, the largest Ebola virus outbreak in human history in West Africa has reached its peak in 2014. The epidemic began to ease in 2015, and it was officially announced in January 2016. The epidemic was nearly 30,000 people infected and more than 11,000 people died. Experts believe that the statistics may be seriously underestimated, and the actual number of deaths is even more. The rate is as high as 71%, which can be said to really frighten all human beings. Now, I can finally relax a little, because the research and development of vaccines has made significant progress.

Since the discovery of the Ebola virus in Sudan and Say in 1976, scientists have started to conduct related virus research. However, before the 2013-2014 outbreak, the Ebola virus was only a small-scale outbreak, such as a small outbreak. The village, but not spread out, the total number of outbreaks of infections was only 1,716 before 2013. Although the mortality rate was as high as 50%, the death of the whole body was quite scary and scary, but the actual number of infections was too small. The mainstream medical profession has paid little attention to it, and only film and television literature has been used as a creative subject.

The big outbreak in 2013~2014 changed this situation. In this big outbreak, not only the scale was large, the number of deaths was large, but also a few cases came to Europe and the United States, which attracted global attention. The research progress of the Ebola virus vaccine was greatly promoted. Clinical trials were conducted in several affected West African countries, where Merck Sharp & Dohme released clinical trial results of its vaccine rVSV-ZEBOV on December 22, 2016 at Lancet. The vaccine is shown to be highly protective.

The clinical trials at Merck's Pharmaceuticals are conducted in Guinea and the Sierra Leone epidemic area. Once someone has been diagnosed with the Ebola virus, the person who has been exposed to the patient within 3 weeks and the person who has been exposed to it have been vaccinated. Injecting methods, 11,841 people participated in the clinical trial, of which 5,837 were in the total number of people who were vaccinated. No one was infected with Ebola, and 23 were not vaccinated. In other words, the vaccine has 100% protection in this clinical trial.

The side effects of the vaccine are also generally quite mild. Of all the perpetrators, only one person has a fever due to vaccination, one person is allergic, and no other person has any significant side effects. The research team's clinical trial results of the vaccine indicated that the next time there will be an Ebola outbreak, humans will no longer be allowed to slaughter, and there will be enough weapons to protect them.

Ebola virus has a solution, Merck completes the vaccine clinical trial

Merck's Pharmaceuticals has been licensed, and the vaccine can be quickly cleared during the US and EU review process. Merck also said that it will start producing vaccines before the approval, and it is scheduled to produce 300,000 doses in case of emergency, vaccine production costs. Up to $5 million will be funded by the Gavi, the Vaccine Alliance, a vaccine charity sponsored by the Bill & Melinda Gates Foundation.

PoE Splitter

The POE splitter is opposite to the POE power supply. POE power supply combines data signal and power, so POE power supply is also called POE combiner. The working process of the POE splitter is just the opposite, which separates the data signal from the power. If data terminals such as network cameras (IPC), wireless APs, and IP phones support POE power supply, you do not need to use a POE splitter when wiring, and you can directly supply power via a network cable. The POE splitter is mainly used for PSE devices such as POE Switches and POE power supplies at the upper end, but the devices connected to the lower end do not support POE. The POE splitter separates the power supply into data signal and power. There are two output lines, one is the power output line, and the other is the network data signal output line, that is, the ordinary network cable. The power output has 5V/9/12V, etc., which can match various DC input non-POE power receiving terminals, and supports the IEEE 802.3af/802.3at standard. The data signal output line, that is, the ordinary network cable, can be directly connected to the network port of the non-POE power receiving terminal.

The POE splitter is used in conjunction with PSE power supply equipment to supply power to network equipment such as wireless APs, wireless routers, IP cameras, and IP phones in a network environment that lacks a power cord or is far from a power outlet. In many monitoring occasions, the best location for monitoring may not be very convenient for equipment to obtain power. The emergence of POE splitters facilitates the integration of equipment that does not support POE power supply into the POE network, and the monitoring equipment does not have to sacrifice the most to take care of the distance of the socket. Optimal installation location.

Poe Splitter,Poe Isolator,Output Poe Splitter,Scodeno Poe Splitter

Shenzhen Scodeno Technology Co.,Ltd , https://www.scodenonet.com